Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1001/jama.2020.6019 http://scihub22266oqcxt.onion/10.1001/jama.2020.6019 32282022!ä!32282022 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JAMA 2020 ; 323 (18): 1824-1836 Nephropedia Template TP {{tp|p=32282022|t=2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review |pdf=|usr=}}{{32282022}} gab.com Text Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review JO: JAMA http://www.kidney.de/pget.php?&tw=1&pmid=32282022 #FOAvip IMPORTANCE: The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. OBSERVATIONS: No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19. CONCLUSIONS AND RELEVANCE: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date. Twit Text FOAVip Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review ????JAMA http://www.kidney.de/pget.php?&tw=1&pmid=32282022 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32282022 #FOAvip English Wikipedia <ref>{{Cite pmid|32282022}}</ref> Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review #MMPMID32282022 Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB JAMA 2020[May]; 323 (18): 1824-1836 PMID32282022show ga IMPORTANCE: The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. OBSERVATIONS: No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19. CONCLUSIONS AND RELEVANCE: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date. |*Betacoronavirus/drug effects/physiology[MESH] |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Adrenal Cortex Hormones/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Amides/therapeutic use[MESH] |Angiotensin Receptor Antagonists/therapeutic use[MESH] |Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Azithromycin/therapeutic use[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Chloroquine/therapeutic use[MESH] |Coronavirus Infections/*drug therapy/epidemiology[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Immunoglobulins/therapeutic use[MESH] |Immunologic Factors/therapeutic use[MESH] |Indoles/therapeutic use[MESH] |Lopinavir/therapeutic use[MESH] |Oseltamivir/therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/epidemiology[MESH] |Pyrazines/therapeutic use[MESH] |Ribavirin/therapeutic use[MESH] |Ritonavir/therapeutic use[MESH] |SARS-CoV-2[MESH]Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Re(epmc).pdf DeepDyve Pubget Overpricing